Ahmet Uluer

Publications

1. Sepsis beyond bundles: contextualising paediatric care in resource-limited settings through situational analysis. BMJ Paediatr Open. 2025 Feb 12; 9(1). View Abstract
2. Contraceptive use and pregnancy in cystic fibrosis: Survey findings from 10 cystic fibrosis centers. J Cyst Fibros. 2025 Jan 22. View Abstract
3. Cystic Fibrosis Experience of Care Survey: Patient-Caregiver-Clinician Collaborative Design and Implementation. J Patient Exp. 2024; 11:23743735241302739. View Abstract
4. Impact of Cystic Fibrosis Transmembrane Conductance Regulator Modulators on Maternal Outcomes During and After Pregnancy. Chest. 2025 Feb; 167(2):348-361. View Abstract
5. Safety and tolerability of a low glycemic load dietary intervention in adults with cystic fibrosis: a pilot study. Front Nutr. 2024; 11:1441201. View Abstract
6. Health care transition quadruple aim outcomes for IDD: Scoping review. Health Care Transit. 2024; 2:100067. View Abstract
7. Healthcare transition readiness of families of youth with cystic fibrosis during COVID-19: A correlational multicenter analysis. Health Care Transit. 2024; 2:100065. View Abstract
8. Continuous glucose monitoring and advanced glycation endproducts for prediction of clinical outcomes and development of cystic fibrosis-related diabetes in adults with CF. Front Endocrinol (Lausanne). 2024; 15:1293709. View Abstract
9. De novo mutations mediate phenotypic switching in an opportunistic human lung pathogen. bioRxiv. 2024 Feb 06. View Abstract
10. Randomized Trial of the Insulin-Only iLet Bionic Pancreas for the Treatment of Cystic Fibrosis- Related Diabetes. Diabetes Care. 2024 Jan 01; 47(1):101-108. View Abstract
11. Cystic fibrosis-related mortality in the United States from 1999 to 2020: an observational analysis of time trends and disparities. Sci Rep. 2023 09 12; 13(1):15030. View Abstract
12. Development and Validation of a Respiratory-Responsive Vocal Biomarker-Based Tool for Generalizable Detection of Respiratory Impairment: Independent Case-Control Studies in Multiple Respiratory Conditions Including Asthma, Chronic Obstructive Pulmonary Disease, and COVID-19. J Med Internet Res. 2023 04 14; 25:e44410. View Abstract
13. Association between unplanned pregnancies and maternal exacerbations in cystic fibrosis. J Cyst Fibros. 2023 09; 22(5):796-803. View Abstract
14. Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials. Lancet Respir Med. 2023 06; 11(6):550-562. View Abstract
15. Continuous Glucose Monitoring and HbA1c in Cystic Fibrosis: Clinical Correlations and Implications for CFRD Diagnosis. J Clin Endocrinol Metab. 2022 03 24; 107(4):e1444-e1454. View Abstract
16. The Relationship between Body Composition, Dietary Intake, Physical Activity, and Pulmonary Status in Adolescents and Adults with Cystic Fibrosis. Nutrients. 2022 Jan 12; 14(2). View Abstract
17. Issues affecting young people with asthma through the transition period to adult care. Paediatr Respir Rev. 2022 Mar; 41:30-39. View Abstract
18. Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis. J Cyst Fibros. 2021 11; 20(6):1026-1034. View Abstract
19. The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis. J Cyst Fibros. 2022 03; 21(2):258-263. View Abstract
20. Favorable Clinician Acceptability of Telehealth as Part of the Cystic Fibrosis Care Model during the COVID-19 Pandemic. Ann Am Thorac Soc. 2021 09; 18(9):1588-1592. View Abstract
21. Family-building and parenting considerations for people with cystic fibrosis. Pediatr Pulmonol. 2022 02; 57 Suppl 1:S75-S88. View Abstract
22. The Effects of Ivacaftor on Bone Density and Microarchitecture in Children and Adults with Cystic Fibrosis. J Clin Endocrinol Metab. 2021 03 08; 106(3):e1248-e1261. View Abstract
23. Men's health in the modern era of cystic fibrosis. J Cyst Fibros. 2021 11; 20(6):e121-e123. View Abstract
24. Integration of mental health screening and treatment into cystic fibrosis clinics: Evaluation of initial implementation in 84 programs across the United States. Pediatr Pulmonol. 2020 11; 55(11):2995-3004. View Abstract
25. Supporting the Medically Fragile: Individualized Approach to Empowering Young Adults With Chronic Disease During the COVID-19 Pandemic. J Adolesc Health. 2020 09; 67(3):453-455. View Abstract
26. Children's Hospitals Caring for Adults During a Pandemic: Pragmatic Considerations and Approaches. J Hosp Med. 2020 05; 15(5):311-313. View Abstract
27. Prevalence and clinical associations of Staphylococcus aureus small-colony variant respiratory infection in children with cystic fibrosis (SCVSA): a multicentre, observational study. Lancet Respir Med. 2019 12; 7(12):1027-1038. View Abstract
28. Antifibrinolytic Agents for Hemoptysis Management in Adults With Cystic Fibrosis. Chest. 2019 06; 155(6):1226-1233. View Abstract
29. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N Engl J Med. 2018 10 25; 379(17):1599-1611. View Abstract
30. Sexual and Reproductive Health of Young Women With Cystic Fibrosis: A Concept Mapping Study. Acad Pediatr. 2019 04; 19(3):307-314. View Abstract
31. A Pilot Study of Inspiratory Muscle Training to Improve Exercise Capacity in Patients with Fontan Physiology. Semin Thorac Cardiovasc Surg. 2018 Winter; 30(4):462-469. View Abstract
32. Overcoming barriers to a successful transition from pediatric to adult care. Pediatr Pulmonol. 2017 Nov; 52(S48):S52-S60. View Abstract
33. Impact of CFTR Modulation on Intestinal pH, Motility, and Clinical Outcomes in Patients With Cystic Fibrosis and the G551D Mutation. Clin Transl Gastroenterol. 2017 Mar 16; 8(3):e81. View Abstract
34. Comparison of Nasal Potential Difference and Intestinal Current Measurements as Surrogate Markers for CFTR Function. J Pediatr Gastroenterol Nutr. 2016 11; 63(5):e92-e97. View Abstract
35. Young adults with cystic fibrosis have altered trabecular microstructure by ITS-based morphological analysis. Osteoporos Int. 2016 08; 27(8):2497-505. View Abstract
36. Risk Factors for Hearing Loss in Patients with Cystic Fibrosis. J Am Acad Audiol. 2016 01; 27(1):6-12. View Abstract
37. Correlations of salivary biomarkers with clinical assessments in patients with cystic fibrosis. PLoS One. 2015; 10(8):e0135237. View Abstract
38. Trends in bone mineral density in young adults with cystic fibrosis over a 15 year period. J Cyst Fibros. 2015 Jul; 14(4):526-32. View Abstract
39. Compromised bone microarchitecture and estimated bone strength in young adults with cystic fibrosis. J Clin Endocrinol Metab. 2014 Sep; 99(9):3399-407. View Abstract
40. An automated integrated platform for rapid and sensitive multiplexed protein profiling using human saliva samples. Lab Chip. 2014 Mar 21; 14(6):1087-98. View Abstract
41. Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis. J Cyst Fibros. 2013 Jan; 12(1):54-9. View Abstract
42. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med. 2010 Nov 18; 363(21):1991-2003. View Abstract
43. Employment experiences among adolescents and young adults with cystic fibrosis. Disabil Rehabil. 2011; 33(11):922-6. View Abstract
44. A safe protocol for rapid desensitization in patients with cystic fibrosis and antibiotic hypersensitivity. J Cyst Fibros. 2009 Dec; 8(6):418-24. View Abstract
45. Sensorineural hearing loss in patients with cystic fibrosis. Otolaryngol Head Neck Surg. 2009 Jul; 141(1):86-90. View Abstract
46. Recovery of Herbaspirillum species from persons with cystic fibrosis. J Clin Microbiol. 2008 Aug; 46(8):2774-7. View Abstract
47. Airway epithelial control of Pseudomonas aeruginosa infection in cystic fibrosis. Trends Mol Med. 2008 Mar; 14(3):120-33. View Abstract
48. Polymerase chain reaction/denaturing gradient gel electrophoresis (PCR/DGGE): sensitivity, band pattern analysis, and methodologic optimization. Am J Dermatopathol. 1999 Dec; 21(6):547-51. View Abstract
49. High-affinity agonist binding is not sufficient for agonist efficacy at 5-hydroxytryptamine2A receptors: evidence in favor of a modified ternary complex model. J Pharmacol Exp Ther. 1997 Feb; 280(2):576-83. View Abstract
50. 5-Hydroxytryptamine2A (5-HT2A) receptor desensitization can occur without down-regulation. J Pharmacol Exp Ther. 1995 Dec; 275(3):1638-46. View Abstract
51. Lymphomatoid papulosis and associated cutaneous lymphoproliferative disorders exhibit a common clonal origin. J Invest Dermatol. 1995 Jul; 105(1):51-5. View Abstract
52. Differential ergoline and ergopeptine binding to 5-hydroxytryptamine2A receptors: ergolines require an aromatic residue at position 340 for high affinity binding. Mol Pharmacol. 1995 Mar; 47(3):450-7. View Abstract
53. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther. 1994 Mar; 268(3):1403-10. View Abstract
Show All Publications Show Fewer Publications